SI3137093T1 - Treatment and prevention of Alzheimer's disease - Google Patents
Treatment and prevention of Alzheimer's disease Download PDFInfo
- Publication number
- SI3137093T1 SI3137093T1 SI201530145T SI201530145T SI3137093T1 SI 3137093 T1 SI3137093 T1 SI 3137093T1 SI 201530145 T SI201530145 T SI 201530145T SI 201530145 T SI201530145 T SI 201530145T SI 3137093 T1 SI3137093 T1 SI 3137093T1
- Authority
- SI
- Slovenia
- Prior art keywords
- aluminum
- alzheimer
- oxyhydroxide
- disease
- oxihydroxide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166354 | 2014-04-29 | ||
| EP14166355 | 2014-04-29 | ||
| PCT/EP2015/059339 WO2015165966A1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of alzheimer's disease (ad) |
| EP15720059.3A EP3137093B1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of alzheimer's disease (ad) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3137093T1 true SI3137093T1 (en) | 2018-01-31 |
Family
ID=53039896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201530145T SI3137093T1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of Alzheimer's disease |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10478454B2 (https=) |
| EP (2) | EP3137093B1 (https=) |
| JP (1) | JP6692755B2 (https=) |
| KR (1) | KR102388363B1 (https=) |
| CN (1) | CN106659738B (https=) |
| AU (1) | AU2015254663B2 (https=) |
| CA (1) | CA2946928C (https=) |
| CY (1) | CY1119674T1 (https=) |
| DK (1) | DK3137093T3 (https=) |
| ES (2) | ES2824763T3 (https=) |
| HR (1) | HRP20171896T1 (https=) |
| HU (1) | HUE037501T2 (https=) |
| LT (1) | LT3137093T (https=) |
| NO (1) | NO3137093T3 (https=) |
| PL (1) | PL3137093T3 (https=) |
| PT (1) | PT3137093T (https=) |
| SI (1) | SI3137093T1 (https=) |
| WO (1) | WO2015165966A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3137094T3 (pl) * | 2014-04-29 | 2023-03-13 | Advantage Therapeutics, Inc. | Leczenie i profilaktyka choroby alzheimera (ad) |
| EP3137097B1 (en) | 2014-04-29 | 2023-06-21 | ADvantage Therapeutics, Inc. | Treatment and prevention of alzheimer's disease (ad) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994016327A1 (en) * | 1993-01-14 | 1994-07-21 | Pollard Harvey B | Methods and compositions for blocking amyloid protein ion channels |
| HUP0004331A3 (en) * | 1997-08-21 | 2001-09-28 | Gerolymatos P N Sa | Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| BR112012024708A2 (pt) * | 2010-03-29 | 2016-06-07 | Novartis Ag | composição de compostos orgânicos |
| PL3137094T3 (pl) * | 2014-04-29 | 2023-03-13 | Advantage Therapeutics, Inc. | Leczenie i profilaktyka choroby alzheimera (ad) |
| EP3137097B1 (en) * | 2014-04-29 | 2023-06-21 | ADvantage Therapeutics, Inc. | Treatment and prevention of alzheimer's disease (ad) |
-
2015
- 2015-04-29 EP EP15720059.3A patent/EP3137093B1/en active Active
- 2015-04-29 ES ES17189527T patent/ES2824763T3/es active Active
- 2015-04-29 AU AU2015254663A patent/AU2015254663B2/en active Active
- 2015-04-29 KR KR1020167033332A patent/KR102388363B1/ko active Active
- 2015-04-29 NO NO15720059A patent/NO3137093T3/no unknown
- 2015-04-29 DK DK15720059.3T patent/DK3137093T3/en active
- 2015-04-29 CN CN201580029861.5A patent/CN106659738B/zh active Active
- 2015-04-29 EP EP17189527.9A patent/EP3269376B1/en active Active
- 2015-04-29 JP JP2016565267A patent/JP6692755B2/ja active Active
- 2015-04-29 US US15/307,082 patent/US10478454B2/en active Active
- 2015-04-29 HU HUE15720059A patent/HUE037501T2/hu unknown
- 2015-04-29 WO PCT/EP2015/059339 patent/WO2015165966A1/en not_active Ceased
- 2015-04-29 LT LTEP15720059.3T patent/LT3137093T/lt unknown
- 2015-04-29 ES ES15720059.3T patent/ES2651537T3/es active Active
- 2015-04-29 SI SI201530145T patent/SI3137093T1/en unknown
- 2015-04-29 HR HRP20171896TT patent/HRP20171896T1/hr unknown
- 2015-04-29 PL PL15720059T patent/PL3137093T3/pl unknown
- 2015-04-29 PT PT157200593T patent/PT3137093T/pt unknown
- 2015-04-29 CA CA2946928A patent/CA2946928C/en active Active
-
2017
- 2017-12-13 CY CY20171101303T patent/CY1119674T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015254663B2 (en) | 2020-04-02 |
| US20170049812A1 (en) | 2017-02-23 |
| EP3269376A1 (en) | 2018-01-17 |
| EP3137093B1 (en) | 2017-09-13 |
| CA2946928C (en) | 2023-01-31 |
| CN106659738A (zh) | 2017-05-10 |
| EP3137093A1 (en) | 2017-03-08 |
| EP3269376B1 (en) | 2020-07-15 |
| AU2015254663A1 (en) | 2016-11-10 |
| ES2824763T3 (es) | 2021-05-13 |
| CY1119674T1 (el) | 2018-04-04 |
| CN106659738B (zh) | 2021-02-09 |
| CA2946928A1 (en) | 2015-11-05 |
| JP6692755B2 (ja) | 2020-05-13 |
| HUE037501T2 (hu) | 2018-08-28 |
| HRP20171896T1 (hr) | 2018-02-23 |
| PL3137093T3 (pl) | 2018-06-29 |
| DK3137093T3 (en) | 2017-12-11 |
| US10478454B2 (en) | 2019-11-19 |
| LT3137093T (lt) | 2017-12-11 |
| KR20160145822A (ko) | 2016-12-20 |
| ES2651537T3 (es) | 2018-01-29 |
| KR102388363B1 (ko) | 2022-04-19 |
| NO3137093T3 (https=) | 2018-02-10 |
| JP2017518275A (ja) | 2017-07-06 |
| WO2015165966A1 (en) | 2015-11-05 |
| PT3137093T (pt) | 2017-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2849758T1 (en) | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| HRP20171512T1 (hr) | Derivati betulina | |
| EA201492021A1 (ru) | Антительный состав | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| MX2012007410A (es) | Compuestos antivirales novedosos. | |
| HRP20110800T1 (hr) | UPORABA 2-6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOKSO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL-4-FLUORO-BENZONITRILA ZA LIJEČENJE DIJABETESA, RAKA, AUTOIMUNIH POREMEĆAJA I ZARAZE HIV-om | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| PH12014501620A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MY169099A (en) | Injectable formulation | |
| EP4342473A3 (en) | Compounds useful in hiv therapy | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| MA42301B1 (fr) | Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| SI3099307T1 (en) | Use of cladribine for the treatment of neuromyelitis of the visual nerve | |
| SI3137093T1 (en) | Treatment and prevention of Alzheimer's disease | |
| FI3137094T3 (fi) | Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen | |
| JP2017515812A5 (https=) | ||
| JP2019531286A5 (https=) | ||
| JP2017514831A5 (https=) | ||
| JP2012526099A5 (https=) | ||
| JP2017518275A5 (https=) | ||
| JP2015524808A5 (https=) |